ABSTRACT:
This study aimed to assess the incidence of chronic hepatitis virus infections, viral reactivation cases, viral load follows up and prognostic significance in different types of hematologic malignancies. We investigated of hepatitis B surface antigen (HBsAg) and IgM-hepatitis C (HCV) among 118 blood samples with different types of malignancies, and follow up the viral load in positive cases after chemotherapy course. Results showed 19 (16.1%) case of viral hepatitis infection belong to HBsAg and IgM-HCV different hematological malignancy. Of these, 15 (12.7%) of HBsAg and 4 (3.4%) of HCV IgM positive cases recorded. More than 50% of hepatitis viral reactivation reported in ALL and NHL patients after chemotherapy treatment. Approximately, the relative risk value (RR) 3.22 (95% Cl 0.78-13.22) of cohort viral hepatitis reactivation similar to odds ratio (OR) value 3.65 (95% Cl 0.81-16.41) for malignancy. Thus, a rising occurrence and reactivation of viral hepatitis along with increasing malignancy incidence than non-malignancy individuals. In this study, the results obtained revealed that the incidence of levels of hepatitis infection (HBsAg and HCV IgM) begins to increase significantly at ALL and NHL than other types of leukemia. Although the lowest prevalence of HCV IgM was seen in studying groups, the HCV IgM reported in four types of malignancy. We showed that the reactivation of hepatitis viral infection mostly in patients aged less than 30 years old accompanied by AML cases, and followed in some cases of ALL, while the reactivation of viral hepatitis in older patients with CLL occurred. However, the mean age of patient malignancy associated with viral hepatitis reactivation was 39.74 ± 4.42 with highly significant between cases. Significantly, the mean viral load decreased after a month of viral therapy (3.646×103IU/ml) compared with before and after three months 16.966×103IU/ml and 23.943×103IU/ml, respectively. Prophylactic antiviral therapy should be administered to viral hepatitis carriers before and during chemotherapy, and maintenance treatment for 6 months to reduce reactivation and exacerbation risk.